Sunesis Pharmaceuticals CEO Unloads 5,000 Shares (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS) CEO Daniel N. Swisher, Jr. unloaded 5,000 shares of Sunesis Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $8.00, for a total transaction of $40,000.00. Following the completion of the transaction, the chief executive officer now directly owns 154,073 shares of the company’s stock, valued at approximately $1,232,584. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 3.73% on Friday, hitting $7.49. The stock had a trading volume of 1,903,154 shares. Sunesis Pharmaceuticals has a 52 week low of $3.84 and a 52 week high of $8.46. The stock has a 50-day moving average of $6.72 and a 200-day moving average of $6.07. The company’s market cap is $452.7 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings data on Tuesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Sunesis Pharmaceuticals will post $-0.74 EPS for the current fiscal year.
Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday.
Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.